Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Prospective Study Assessing the Relationship Between Expression of the Norepinephrine Transporter and 18F-mFBG PET Imaging Results in Neuroblastoma Tumor, Other Neural Crest Tumors, and Organs Innervated by the Sympathetic Nervous System
This is a prospective Phase 2 study being performed to document the relationship between 18F-mIBG positron emission tomography (PET) findings in subjects, and expression of the norepinephrine transporter. In addition to collecting safety data for the imaging agent, the study aims to:
* compare the findings against other catacholamine transporters
* evaluate the imaging results at different time points and in different organs
* assess the quality of images with lower doses
* compare the ability to detect neuroblastoma lesions against other imaging agents, and in other tumors
A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
An Open-Label, Exploratory, Phase 1/2 Scintigraphy Study Evaluating 18F-mFBG for Imaging Myocardial Sympathetic Innervation in Subjects Without and With Heart Disease
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
100 Clinical Results associated with Illumina Radiopharmaceuticals LLC
0 Patents (Medical) associated with Illumina Radiopharmaceuticals LLC
100 Deals associated with Illumina Radiopharmaceuticals LLC
100 Translational Medicine associated with Illumina Radiopharmaceuticals LLC